Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.29 -0.09 (-0.23%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,469,955
Open 39.18
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.38
Today's Range 39.12 - 39.42
52wk Range 37.88 - 53.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
 
Via Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
 
Via Benzinga

Performance

YTD
+0.05%
+0.05%
1 Month
+0.31%
+0.31%
3 Month
-5.58%
-5.58%
6 Month
-5.26%
-5.26%
1 Year
-17.63%
-17.63%

More News

Read More
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
From Genentech
Via Business Wire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Via Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
Via Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
Via Investor's Business Daily
Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today
Via Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
Via Benzinga
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
From Genentech
Via Business Wire
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Via Investor's Business Daily
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
Via The Motley Fool
Big Health Care Stocks to Watch in the New Year
Via MarketBeat
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
Via Investor's Business Daily
Roche's Follicular Lymphoma Therapy Scores FDA Approval
Via Benzinga
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
Via Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Via Investor's Business Daily
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
Via Talk Markets
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Via InvestorPlace
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Via Investor's Business Daily
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Via MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
Via TheNewswire.com
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.